What is Indivior Pharmaceuticals, Inc. 's estimated litigation liability?

Indivior Pharmaceuticals, Inc. (INDV) reported estimated litigation liability of $55M in Q1 2026.

How has Indivior Pharmaceuticals, Inc. 's estimated litigation liability changed year-over-year?

Indivior Pharmaceuticals, Inc. 's estimated litigation liability decreased by 86.3% year-over-year, from $402M to $55M.

Revenue$317.0M+19.2%

Gross profit$277.0M+24.8%

Operating income$137.0M+108%

Net income$89.0M+89.4%

EPS (diluted)$0.69+81.6%

Cash & equivalents$175.0M-53.0%

Total debt$509.0M+37.6%

Total equity-$144.0M+49.5%

Total assets$1.2B-12.9%

Operating cash flow-$9.0M-112%

CapEx$20.0M+300%

Free cash flow-$29.0M-141%

Market cap$4.53B+213%

Gross margin81.3%+1.5pp

Operating margin25.8%+23.3pp

Net margin19.4%+18.9pp

FCF margin-14.9%—

Current ratio0.9×0.0×

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LitigationReserve.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

What is Indivior Pharmaceuticals, Inc. 's estimated litigation liability?: Indivior Pharmaceuticals, Inc. (INDV) reported estimated litigation liability of $55M in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's estimated litigation liability changed year-over-year?: Indivior Pharmaceuticals, Inc. 's estimated litigation liability decreased by 86.3% year-over-year, from $402M to $55M.